Natera stock falls nearly 6% as sellers override momentum despite strong phase III trial news

Traders Union
All News
Stocks
Natera slides 5.71% today to $401.33

Highlights

Natera initiated a global phase III trial with Alliance Foundation Trials and Genentech to assess MRD-guided therapy in early breast cancer.
Japanese regulators approved Signatera as a companion diagnostic in muscle-invasive bladder cancer, and Natera settled a billing class action for $9.5 million.
Natera stock trades above key moving averages with strong momentum, but is currently under selling pressure near support at $401.08 with an expected short-term range of $383.5 to $419.18.

Broad selling persists as strong revenue and trial launch drive news flow

Natera initiated the AFT-70 NAVIGATE global, randomized phase III trial in partnership with Alliance Foundation Trials and Genentech to evaluate an MRD-guided treatment strategy in over 2,000 patients with early breast cancer. Regulatory approval was granted in Japan for Signatera as a companion diagnostic in muscle-invasive bladder cancer. The company reported Q2 2026 revenue of $752.75 million, marking a 37.7% year-over-year increase. Natera also agreed to pay $9.5 million to settle a class action lawsuit related to billing communications, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, observes that Natera's sharp drop contrasts with otherwise positive business milestones. He notes that the ongoing lawsuit settlement and market volatility have injected caution despite robust technical momentum and revenue growth. Kharitonov is wary of the overbought technical readings and sees a risk that the positive trend is fragile when sentiment turns. He emphasizes that the elevated BBP and intraday volatility warn of possible profit-taking. "Despite the bullish structure, I see a real risk of a technical correction if sentiment deteriorates or sellers escalate," he states.

Viktoras Karapetjanc, expert at Traders Union, highlights the constructive outlook for Natera. He points to strong revenue growth, regulatory advances, and a landmark global trial as powerful drivers for further gains. Karapetjanc views the technical setup as bullish — moving averages, momentum, and institutional interest all favor buyers. He believes the dip is a healthy pause before renewed upside. "The bullish structure remains intact and I expect the stock to resume its upward trajectory as regulatory and trial progress unlock more value," he says.

Parshwa Turakhiya, analyst, sees strong technical momentum in Natera but flags near-term overbought signals. He believes the current pullback is a sentiment-driven response rather than a breakdown in trend. Turakhiya notes that both support at $401.08 and resistance at $419.18 are key levels for short-term setups, with intraday volatility offering tactical opportunities. "I see active traders watching for either a bounce from support or a momentum breakout above $419.18 in the coming sessions," he comments.

Overbought signals intensify as bullish bias meets intraday selling

Natera trades well above its 20-day ($377.13), 50-day ($334.38), and 200-day ($250.05) moving averages, confirming bullish structure across short-, medium-, and long-term horizons. Near-term levels to watch are support at $401.08 and resistance at $419.18. Momentum remains strong, with the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both indicating buy signals. The Relative Strength Index (RSI) and Stochastic RSI are in overbought territory, suggesting limited upside in the very near-term, and the Commodity Channel Index (CCI) signals persistent bullish momentum. Bull/Bear Power (BBP) remains positive at 27.48, confirming buyers currently dominate intraday, but this is flagged as overbought. The stock is down today, last quoted at $401.33 after an upside gap of about $3.37 (0.79%) at the open, and now sits near the low end of its daily range with intraday volatility at 9.87%. Sellers have exerted pressure since the open, which is somewhat at odds with the ongoing momentum signals.

Previously it was reported that Natera’s entry into the Japanese market and sustained technical momentum positioned the stock for continued upside. The current pullback contrasts with earlier strength, and traders should watch for consolidation above the $383.5 support as a signal for whether the bullish trend remains intact.

Source of Data: NTRA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.